These findings suggest that TRAIL decreases the viability of ANT2 shRNA-treated MCF7 breast cancer cells by inducing apoptosis through a mechanism mediated by caspase-7, -8, and -9 and involving the intrinsic mitochondrial apoptosis pathway. Here, CASP7 is linked to breast cancer.